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AbstrACt
Objectives To investigate men’s values and preferences 
regarding prostate-specific antigen (PSA)-based screening 
for prostate cancer.
Design Systematic review.
Data sources We searched MEDLINE, EMBASE, PsycINFO 
and grey literature up to 2 September 2017.
Eligibility criteria Primary studies of men’s values and 
preferences regarding the benefits and harms of PSA 
screening.
Data extraction and synthesis Two independent 
reviewers extracted data and assessed risk of bias 
with a modified version of a risk of bias tool for 
values and preferences studies, the International 
Patient Decision Aid Standards instrument V.3 and the 
Cochrane Collaboration risk of bias tool.
results We identified 4172 unique citations, of which 
11 studies proved eligible. Five studies investigated 
PSA screening using a direct choice study design, 
whereas six used decisions aids displaying patient-
important outcomes. The direct choice studies used 
different methodologies and varied considerably in 
the reporting of outcomes. Two studies suggested 
that men were willing to forego screening with a 
small benefit in prostate cancer mortality if it would 
decrease the likelihood of unnecessary treatment or 
biopsies. In contrast, one study reported that men 
were willing to accept a substantial overdiagnosis 
to reduce their risk of prostate cancer mortality. 
Among the six studies involving decision aids, 
willingness to undergo screening varied substantially 
from 37% when displaying a hypothetical reduction 
in mortality of 10 per 1000 men, to 44% when 
displaying a reduction in mortality of 7 per 1000. 
We found no studies that specifically investigated 
whether values and preferences differed among men 
with family history, of African descent or with lower 
socioeconomic levels.
Conclusion The variability of men’s values and 
preferences reflect that the decision to screen is 
highly preference sensitive. Our review highlights the 
need for shared decision making in men considering 
prostate cancer screening.
trial registration number CRD42018095585.
IntrODuCtIOn 
Population prostate-specific antigen (PSA)-
based screening for prostate cancer remains 
controversial. Although PSA screening leads 
to increased incidence of prostate cancer, it 
results at best in a small absolute reduction 
in disease-specific mortality (1 fewer deaths 
per 1000 men over 10 years).1 It is unclear 
whether the overall benefits of screening 
outweigh the potential harms and burden 
resulting from the cascade of diagnostic 
imaging and biopsies (eg, bleeding, pain, 
infections and hospital readmissions), as 
well as complications from subsequent pros-
tate cancer treatment (eg, urinary inconti-
nence, erectile dysfunction or bowel-related 
complaints).1 This uncertainty is reflected by 
a lack of consensus across international guide-
lines,2–7 as well as the important variability of 
the screening practices worldwide.8–14 
strengths and limitations of this study
 ► We systematically searched for and assessed the 
quantitative values and preferences related to ben-
efits and harms of prostate-specific antigen (PSA) 
screening among men considering screening, to 
inform a linked BMJ Rapid Recommendations 
guideline.
 ► We used rigorous systematic review methodology, 
and a guideline panel of frontline clinicians, method-
ologists and patient partners identified patient-im-
portant outcomes related to PSA screening.
 ► We did not identify studies that explicitly asked men 
about the thresholds of benefits and harms related 
to PSA screening that would be important to them.
 ► Most studies included several characteristics of 
screening options (eg, costs and time  intervals), 
which might influence the willingness to undergo 
screening more than potential benefits and harms.
 ► A meta-analysis was not possible, thus we reported 
a narrative summary of the included studies.
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Because prostate cancer will often—although not always—
remain indolent, and result in substantial overdiagnosis 
and overtreatment, the decision to undergo PSA screening 
is highly preference-sensitive. Men who place a high value 
in avoiding complications from biopsies and subsequent 
treatment may be more likely to decline screening, whereas 
men who place a higher value in even a small reduction of 
prostate cancer, as well as those who are more concerned 
to rule out the diagnosis, are likely to choose screening.2 
Decision aids may facilitate understanding of the benefits 
and harms of alternative choices in decision making, and 
help men to make a decision in line with their own values 
and preferences.15 16
A large cluster randomised trial of PSA testing conducted 
among 419 582 British men in general practices triggered 
a BMJ Rapid Recommendation (RapidRec) guideline2 17 
— a series of trustworthy recommendations published in 
response to potentially practice-changing evidence.18 An 
international panel appraised the whole body of evidence 
in an updated systematic review of the benefits and harms 
of PSA screening for prostate cancer,1 and issued a recom-
mendation2 (box 1). Men’s preferences about undergoing 
screening, when presented with information about the 
potential benefits and harms, remains unclear. To inform 
the RapidRec guideline work, we conducted this systematic 
review to examine men’s values and preferences regarding 
prostate cancer screening.
MEthODs
The study protocol was registered in the International 
Prospective Register of Systematic reviews: CRD42018095585. 
We followed the Meta-analysis of Observational Studies 
in Epidemiology (MOOSE) reporting guidelines for this 
article (see online supplementary appendix I).
Eligibility criteria
We included studies that reported men’s stated prefer-
ence to screen or not to screen, based on their values and 
preferences concerning PSA screening patient-important 
benefits and harms, as defined by the BMJ RapidRecs guide-
line panel.2 Additionally, we examined the stated intention 
to undergo screening based on information regarding the 
patient-important outcomes presented in decision aids. We 
excluded: (1) analyses of data that were not reported by 
patients (eg, databases of health records) or on outcomes 
outside the perspective of men considering prostate cancer 
screening; (2) studies reporting only outcome prioritisa-
tion, time trade off, health state values or willingness to pay; 
(3) studies reporting only access to screening; (4) studies 
on knowledge or awareness about screening; (5) cost-effec-
tiveness studies; (6) qualitative studies; (7) case report and 
case series and (8) studies published in a language other 
than English.
search strategy
We searched MEDLINE, EMBASE and PsycINFO from 
1980 to 2 September 2017, using a combination of 
keywords and MeSH/EMTREE terms related to prostate 
cancer and cancer screening, and applied a search filter for 
patient’s values and preferences19 (see online supplemen-
tary appendix II). Additionally, we searched the conference 
abstracts from the annual meetings of the European Asso-
ciation of Urology and American Urological Association 
from 2007 to 2017. We also searched through Google for 
‘prostate cancer screening’ and ‘values and preferences’, 
reviewing the first five pages of results. References of the 
included studies were screened to identify other potentially 
eligible studies.
study selection and quality assessment
We screened titles and abstracts, as well as full-text 
screening, independently and in duplicate by paired 
reviewers (RV, LL, HP, CC, LA, KC). Disagreements 
were resolved by consensus or consultation with a a third 
reviewer (TA). The risk of bias was assessed independently 
and in duplicate. For studies that reported men’s stated 
preferences about prostate cancer screening (eg, discrete 
choice experiments), we used a risk of bias tool developed 
specifically for values and preferences studies.20 For studies 
that investigated the effect of decision aids on men’s inten-
tions to undergo screening, we used two instruments, 
similar to a recent study of decision aids for prostate cancer 
screening.21 First, we assessed the risk of bias using a modi-
fied version of the Cochrane Collaboration risk of bias tool 
addressing randomisation sequence generation, conceal-
ment, blinding of data collectors, blinding of data analysts 
and missing data—separately for each outcome. For each 
criterion, studies were judged to be at either high, unclear 
or low risk of bias. Additionally, we evaluated the decision 
aids using a modified version of the International Patient 
Decision Aid Standards instrument V.3 for screening.22 We 
rated each criterion as met or not met. The full risk of bias 
assessments can be found in the online supplementary 
appendix III.
box 1 Linked articles in this bMJ rapid recommendation 
cluster
 ► Tikkinen KAO, Dahm P, Lytvyn L,  et al . Prostate cancer screening 
with prostate-specific antigen (PSA) test: a clinical practice guide-
line.  BMJ  2018:362:k3581. doi:10.1136/bmj.k3581.2 
 ► Summary of the results from the Rapid Recommendation process 
 ► Ilic D, Djulbegovic M, Jung JH,   et al . Prostate cancer screening 
with prostate-specific antigen (PSA) test: a systematic review and 
meta-analysis.  BMJ  2018:362:k3519. doi:10.1136/bmj.k3519.1 
 ► Systematic review and meta-analysis of all available randomised 
trials that assessed PSA based screening for prostate cancer. 
 ► Vernooij RWM, Lytvyn L, Pardo-Hernandez H,  et al . Values and pref-
erences of men for undergoing prostate-specific antigen screening 
for prostate cancer: a systematic review.  BMJ Open   2018. 
 ► MAGICapp (https:// app. magicapp. org/ public/ guideline/ n32gkL). 
 ► Expanded version of the results with multilayered recommenda-
tions, evidence summaries, and decision aids for use on all devices. 
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Data collection and presentation
Two reviewers extracted the data from the included studies, 
independently and in duplicate, using a standardised form, 
including: first author, publication year, study design (eg, 
discrete choice experiment, decision aids study), setting, 
number of participants, participant’s demographics (eg, 
age, previous screening, prostate cancer family history). For 
decision-aids studies, we reported the intention to screen 
after exposure to the decision aids. Due to the heteroge-
neity of the data, we summarised the study results in a narra-
tive format.
bMJ rapid recommendations and patient involvement
A panel of clinicians, including urologists, family doctors, 
methodologists and men considering screening, were 
responsible for creating rapid and trustworthy recom-
mendations.1 2 Three men eligible for PSA screening were 
members of the guideline panel that informed the protocol 
for this review, and received personal training and support 
to optimise contributions throughout the guideline devel-
opment process. These panel members identified and prior-
itised patient-important outcomes, and led the discussion 
on values and preferences. The guideline panel defined 
the population and all patient-important outcomes of 
interest, as well as practical issues related to PSA screening. 
To provide the guideline panel with the best available 
evidence, a linked systematic review was conducted that 
summarised outcomes related to the benefits and harms 
of PSA screening.1 The BMJ RapidRec panel developed 
recommendations using the Grading of Recommendations, 
Assessment, Development and Evaluation framework, and 
considered both the evidence from the systematic review 
on the effectiveness and safety of PSA screening, and the 
evidence from this review on men’s values and preferences.23 
Finally, the results of the two reviews and the panel delibera-
tions were used to inform the online consultation decision 
aids generated from the evidence summary supporting this 
BMJ RapidRec,2 available online through the MAGICapp 
(www. magicapp. org).
rEsuLts
study characteristics
We identified 4172 unique citations, of which 200 
proceeded to full-text review (see online supplemen-
tary appendix IV for the reasons of exclusion). Eleven 
Figure 1 Flow chart of the search strategy and evidence selection of the included studies.
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studies were ultimately eligible for our review (figure 1). 
Of the included studies, five investigated men’s stated 
preferences regarding prostate cancer screening,24–28 and 
six investigated men’s willingness to undergo screening 
when presented with a decision aid.29–34
The studies were all conducted in high-income 
countries: Australia (1), The Netherlands (1), the UK 
(1), the USA (7) and both the USA and Australia (1) 
(table 1). The proportion of men who had previously 
undergone prostate cancer screening prior to study 
participation varied from 0% to 80% across studies. 
Similarly, the proportion of men with prostate cancer 
family history varied from 0% to 27%. In one study, 
51% of the included men reported to know someone 
that had prostate cancer without any further defi-
nition.25 Of the studies that reported their funding 
source (82%), all were sponsored by public grant 
institutions. About half of the studies (55%) stated 
that the authors did not have any relevant conflicts of 
interest, and the other studies did not report about 
authors’ conflicts of interest.
study quality
Most stated preference studies were of moderate to high 
risk of bias, usually due to limitations in the attrition 
and data analysis domains (table 2). One study included 
participants from the general population25; however, the 
other studies mainly referred to outpatients or research 
panel participants. However, most of the studies did not 
report enough information to assess the attrition bias, 
only de Bekker-Grob et al.25 reported the survey response 
rate (46%).25 Only one study was considered at low risk 
of bias in the measurement instrument subdomain.26 In 
this study, the authors adequately used an instrument 
for electing the relative importance of valid and reliable 
outcomes, administered the instrument in the intended 
Table 1 Characteristics of the included studies
Study Design Country
Years of 
data collection
Number of 
participants
Age 
(mean, 
SD)
Previous PSA 
screening
Family history 
of prostate 
cancer
Studies reporting direct choice related to PSA screening acceptability
  Cantor et al24 DCE USA 1997–1998 168 56 (NR) Ever=50%
Unsure=14%
17% have 
relative with 
prostate cancer
  de Bekker-Grob et al25 DCE The 
Netherlands
2013 1000 63.3 (5.2) NR 51% know 
someone with 
prostate cancer
  Howard et al26 and 
Pignone et al29 
DCE Australia 
and USA
2011 911 59.8 (5.6) Ever=20.9%
Within past 
year=42%
0%
  Howard et al27 DCE USA NR 662 55 (9) Ever=44.6%
Within past 
year=28.1%
0%
  van den Bruel et al28 DCE UK 2014 490 46.9 
(range: 
19–87)
Ever=53.8% NR
Studies of decision aids reporting men’s willingness to undergo PSA screening
  Gattellari and Ward30 RCT Australia NR 258 54 (8.55) NR NR
  Petrova et al31 RCT USA NR 256 36 (13) Ever=18% 27% had 
a friend or 
a relative 
diagnosed with 
prostate cancer
  Sheridan et al32 RCT USA NR 188 60 (9) Ever=70% 20% had any 
family history
  Sheridan et al33 RCT USA NR 775 NR Ever=80% NR
  Taylor et al34 RCT USA 2007–2011 1893 56.9 (6.8) Ever=86.3%
Within past 
year=59.3%
23% had family 
history
  Wilt et al35 RCT USA 1998 342 72.8 (8.4) Within past 
year=31%
14%
DCE, discrete choice experiment; NR, not reported; PSA, prostate-specific antigen; RCT, randomised controlled trial.
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way and used a valid representation of the outcome. 
None of the studies formally tested the understanding of 
the used instruments.
The decision-aids studies were mostly of low to moderate 
risk of bias; however, there were several methodological 
limitations (see online supplementary appendix V). One 
study applied adequate random sequence generation and 
allocation concealment.33 Due to the nature of the inter-
vention, most patients were aware of the allocated inter-
vention. Moreover, blinding procedures for the outcome 
collector or analysts were not reported; however, risk of 
bias for random allocation or blinding was not considered 
important for this review since we are interested solely 
in the results after exposure. Four studies described the 
amount of missing data.29 32–34 Furthermore, most studies 
described the aim of screening, but only two (33%) deci-
sion-aids studies included information about the rates of 
diagnostic test accuracy. Similarly, less than half of the deci-
sion aids in the included studies described the next steps 
in the patient’s pathway after obtaining the screening result 
(positive or negative).
stated preferences related to PsA screening
In total, there were five studies on men’s stated prefer-
ences related to prostate cancer screening, all of which 
were discrete choice experiments.24–29 One study included 
a discrete choice experiment, as well as a balance sheet 
task (unlabelled descriptions of the options).26 29 Although 
studies displayed estimates on patient-important benefits 
(risk reduction of prostate cancer-specific mortality) and 
harms (eg, increased unnecessary biopsies, unnecessary 
treatment, risk of incontinence and bowel problems and 
risk of impotence), the objectives of the studies differed and 
the outcomes reported were heterogeneous. A meta-anal-
ysis was therefore not possible, and we summarised the 
evidence narratively (table 3).
The study by de Bekker-Grob et al25 investigated how much 
men are willing to forego screening, if it involved a small 
benefit in prostate cancer mortality, in order to decrease 
the likelihood of unnecessary biopsies, unnecessary treat-
ments and more frequent screening.25 For example, partic-
ipating men were willing to trade a 2.0% (95% CI 1.6 to 
2.4) and 1.8% (95% CI 1.3 to 2.3) decrease in mortality risk 
reduction, for a 10% decrease in unnecessary treatment 
risk and unnecessary biopsy risk, respectively.
In the study by Howard et al, participating men were asked 
how many extra men who would experience unnecessary 
biopsies or incontinence and bowel problems were accept-
able in order to avoid one prostate cancer death.27 These 
results are stratified by age, and were markedly different 
between the age categories. Men aged 50–59 years were 
willing to accept 233 in 10 000 (95% CI 224 to 242) extra 
men with unnecessary biopsies to avoid one prostate cancer 
death in 10 000 men screened, whereas both younger (aged 
40–49 years) and older (aged 60–69 years) men accepted 
fewer unnecessary biopsies. Similarly, men aged 50–59 
years were willing to accept 72 in 10 000 (95% CI 69 to 75) 
extra men with incontinence or bowel problem to avoid 
one prostate cancer death in 10 000 men screened, but this 
was lower in both younger and older men.27
In the study by van den Bruel et al,28 the authors exam-
ined the number of cases of overdetection that the men 
were willing to accept for a reduction in cancer-specific 
mortality.28 To reduce the prostate cancer mortality by 10% 
and 50%, the participating men were willing to accept 126 
(95% CI 100 to 150) and 231 (95% CI 200 to 250) cases 
of overdetection in 1000 people screened, respectively. The 
authors concluded that there was variability in the accept-
ability of overdetection in cancer screening.
Finally, in the study reported by Pignone et al29 and 
Howard et al,26 the chances of prostate cancer diagnosis, 
prostate cancer mortality, biopsies and developing impo-
tence or incontinence as a result of screening were included, 
and men were asked about their willingness to undergo 
screening using three different values elicitation tech-
niques.26 The proportion of men who wanted to undergo 
PSA screening compared with no screening ranged from 
20% to 44%.
studies of decision aids and men’s intentions to undergo 
screening
In total, we identified six studies in which decision aids 
displaying screening-related patient-important outcomes 
(eg, prostate cancer diagnosis, prostate cancer mortality 
risk, unnecessary biopsy risk) were presented to men, and 
asking for their willingness to get screened.30–35 The deci-
sion aids presented information in different ways, which 
resulted in considerable heterogeneity in how outcomes 
were reported (table 4).
The study by Gattellari et al,30 presented a pros-
tate cancer diagnosis in 10% of the men aged up to 
75 years, whereas Sheridan et al32 presented a pros-
tate cancer diagnosis of 5% of men aged 50 years and 25% 
of men aged 70 years.30 32 Furthermore, Taylor et al34 used 
a prostate cancer diagnosis of 16% of all men, and Wilt 
et al35 presented that 10% of all men get prostate cancer.34 35 
Although variability in the presentation of the outcome 
prostate cancer mortality was identified, the quantitative 
effect estimates were comparable, since all studies report 
a prostate cancer mortality of around 1%–3%. Finally, two 
studies included quantitative information on the effect of 
unnecessary biopsies and treatment. This includes a propor-
tion of 30% of the men that experience serious infection 
due to biopsies,33 and a larger variability on the unnecessary 
treatment information, from 30% sexual and urinary prob-
lems due to treatment to 2% unnecessary treatments.31 33
DIsCussIOn
Principal findings
We have conducted the first systematic review of values and 
preferences of men from the general population related 
to their willingness to undergo prostate cancer screening. 
Overall, there was considerable heterogeneity across men’s 
values and preferences regarding the important benefits 
and harms related to prostate cancer screening. Several, 
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but not all, studies reported that many men among the 
general population were willing to accept considerable 
risk of harm such as unnecessary biopsies, risk of impo-
tence and risk of incontinence, in order to achieve a small 
reduction in their risk of prostate cancer mortality. It is 
unclear, however, how much of the variability in prefer-
ences was due to the differences in study methodology and 
reporting.
Table 3 Results of the studies reporting direct choice related to PSA screening acceptability
Study Outcome/presentation Results
Cantor et al24 Preference for PSA screening or no screening, based 
on individualised decision-analytic model.
 ► 28.6% of men preferred screening to no screening.
 ► 34.5% of couples (men and their wives) preferred 
screening to no screening.
de Bekker-
Grob et al25
Willingness to trade per cent decrease in screening-
related mortality risk reduction (from 3.5% to 
3.2%, 10% RRR; 2.8%, 20% RRR; 2.5%, 30% RRR; 
1.8%, 50% RRR), per cent decrease in burden from 
unnecessary biopsies (20%, 40%, 60%, 80%) and 
unnecessary treatments (0%, 20%, 50%, 80%).
 ► 2.0% decrease in screening-related mortality risk 
reduction (95% CI 1.6 to 2.4) for 10% less risk of 
unnecessary treatment.
 ► 1.8% decrease in screening-related mortality risk 
reduction (95% CI 1.3 to 2.3) for 10% less risk of 
unnecessary biopsies.
Howard et al26 
and Pignone 
et al29
Preference for a PSA screening option compared with 
a no screening option, based on a discrete choice 
experiment*, and balance sheet task (unlabelled 
description of benefits and harms)†, over 10 years.
 ► Balance sheet: 43.7% prefer the PSA screening 
option.
 ► Discrete choice experiment: 20.2% prefer the PSA 
screening option.
Howard et al27 Preference for the number of men who would 
experience screening-related harms (unnecessary 
biopsies, incontinence/bowel problems) to avoid one 
prostate cancer death in 10 000 men screened.
Men aged 40–49 years:
 ► 65 in 10 000 (95% CI 59 to 70) extra men with 
unnecessary biopsies.
 ► 31 in 10 000 (95% CI 28 to 34) extra men with 
incontinence/bowel problems.
Men aged 50–59 years:
 ► 233 in 10 000 (95% CI 224 to 242) extra men with 
unnecessary biopsies.
 ► 72 in 10 000 (95% CI 69 to 75) extra men with 
incontinence/bowel problems.
Men aged 60–69 years:
 ► 153 in 10 000 (95% CI 149 to 158) extra men with 
unnecessary biopsies.
 ► 54 in 10 000 (95% CI 52 to 55) extra men with 
incontinence/bowel problems.
van den Bruel 
et al28
Willingness to accept overdetection to trade off 
reduction in prostate cancer-specific mortality.
10% prostate cancer-specific reduction in mortality, 
126 cases (95% CI 100 to 150) of overdetection per 
1000 people screened:
 ► 5.5% (95% CI 3.7 to 7.9) accepts no overdetection 
at all.
 ► 7.1% (95% CI 5.0 to 9.8) accepts overdetection in 
the complete population
50% prostate cancer-specific reduction in mortality, 
231 cases (95% CI 200 to 250) of overdetection per 
1000 people screened:
 ► 4.5% (95% CI 2.8 to 6.7) accepts no overdetection 
at all.
 ► 9.2% (95% CI 6.8 to 12.1) accepts overdetection in 
the complete population.
*Discrete choice experiment, levels of attributes, over 10 years: chance of prostate cancer diagnosis 40 in 1000, 60 in 1000 or 80 in 1000 
with screening, vs 40 in 1000 with no screening; chance of dying from prostate cancer 2 in 1000, 3 in 1000 or 4 in 1000 with screening, vs 4 
in 1000 with no screening; chance of having a prostate biopsy as a result of screening 0 in 1000, 240 in 1000 or 330 in 1000 with screening, 
vs 0 in 1000 with no screening; chance of becoming impotent or incontinent as a result of screening 0 in 1000, 10 in 1000 or 20 in 1000 with 
screening, vs 0 in 1000 with no screening.
†Balance sheet task, features of options, over 10 years: chance of prostate cancer diagnosis for 40 out of 1000 men with no screening, vs 80 
out of 1000 men with screening; chance of dying from prostate cancer for 4 out of 1000 men with no screening, vs 3 out of 1000 men with 
screening; chance of having a prostate biopsy as a result of screening for 0 out of 1000 men with no screening, vs 240 out of 1000 men with 
screening; chance of becoming impotent or incontinent as a result of screening for 0 out of 1000 men with no screening, vs 20 out of 1000 
men with screening.
 PSA, prostate-specific antigen; RRR, relative risk reduction. 
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Context in relation to previous research
Patients’ values and preferences encompass perspectives, 
priorities, beliefs, expectations, values and goals for health 
and life when considering the potential benefits, harms, 
costs and inconveniences of management options avail-
able.36 To inform the RapidRecs guideline,2 we limited our 
scope to quantitative data on thresholds related to bene-
fits and harms, which was deemed the most important 
information for the panel’s decision making. There is 
currently no formal guidance for conducting systematic 
reviews of patients’ values and preferences to inform deci-
sion makers.37 38 Clinical practice guidelines have used 
values and preferences studies to inform outcome impor-
tance, such as measures of health state utilities as well as 
non-utilities (eg, questionnaires, qualitative studies).20 39 
In addition, qualitative research on values and prefer-
ences in particular have been used for contextualising 
guidelines with regard to feasibility and acceptability of 
interventions, and identifying barriers and facilitators to 
implementation of recommendations.40
A recent qualitative review on men’s perspectives of 
prostate cancer screening identified five themes that influ-
ence men’s choices about screening: social prompting, 
gaining decisional confidence, preserving masculinity, 
avoiding the unknown and uncertainties and prohib-
itive costs.41 The review did not discuss the degree of 
benefits and harms considered important nor report on 
heterogeneity across individuals’ perceptions; however, 
the authors highlighted the ‘complex decisional matrix’ 
of deciding whether to be screened. Another systematic 
Table 4 Results of the studies that examined the effect of a decision aid on the men’s motivation for undergoing 
PSA screening
Study
Patient-important outcomes presented in the 
decision aid
Results (men who got randomised to the 
decision-aid arm, unless otherwise stated)
Gattellari et al30 Prostate cancer diagnosis: 10% up to age 75 years.
Prostate cancer mortality: 1 out of 100 men will die 
from prostate cancer.
Interest in having PSA test in the upcoming 
12 months:
 ► Definitely: 26% (95% CI 18 to 35)
 ► Quite a lot: 11% (95% CI 6 to 11)
 ► Somewhat: 19% (95% CI 12 to 27)
 ► A little: 25% (95% CI 16 to 33)
 ► Definitely not interested 23% (95% CI 15 to 31)
Petrova et al31 Prostate cancer mortality: 7 of 1000 men who 
participated in screening and 7 of 1000 men who did 
NOT participate in screening.
Unnecessary treatment: 20 of 1000 men who 
participated in screening and 0 of 1000 men who did 
NOT participate in screening.
 ► Intended to participate in screening: 44%.
 ► Intended to not participate in screening: 37%.
Sheridan et al32 Prostate cancer diagnosis: 5 out of every 100 men 
who are aged 50 years have prostate cancer, whereas 
25 out of every 100 men aged 70 years have prostate 
cancer.
Prostate cancer mortality: 3 of every 100 men die from 
prostate cancer.
 ► Interested in screening: 78%*
Sheridan et al33 Prostate cancer mortality:
 ► Without screening over 10 years: 4 out of 1000 men.
 ► With screening over 10 years: 3 out of 1000 men.
 ► Benefits of screening over 10 years: fewer death in 
1 out of 1000 men.
Unnecessary biopsies: moderate-to-serious infection 
or bleeding due to biopsies in 300 out of 1000 men.
Unnecessary treatment: sex and urine problems due to 
treatment: 300 out of 1000 men.
Intent to accept screening, presented as a range 
of 1–5 (high scores indicate stronger intention to 
accept screening):
 ► Decision aid with a focus on the number 
presentation: 3.63 (SD: 1.15).
 ► Decision aid with a focus on the narrative 
presentation: 3.53 (SD: 1.24).
 ► Decision aid with a focus on the numbers and 
frame: 3.88 (SD: 1.06).
Taylor et al34 Prostate cancer diagnosis: about 1 of every 6 (16%) 
men will be diagnosed with prostate cancer.
Prostate cancer mortality: about 1 out of every 33 (3%) 
men will die from prostate cancer.
Self-reported screening at 13 months:
 ► PSA screening: 45.3%.
 ► DRE screening: 46.8%.
 ► Combined PSA+DRE screening: 59.5%.
Wilt et al 35 Prostate cancer diagnosis: 10% of the men get 
prostate cancer.
Prostate cancer mortality: 70%–80% who have 
prostate cancer do not die from it.
 ► 31% received a PSA test in the year after.
*All study participants (not randomised trial).
DRE, digital rectal examination; PSA, prostate-specific antigen.  o
n
 10 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025470 on 5 September 2018. Downloaded from 
9Vernooij RWM, et al. BMJ Open 2018;8:e025470. doi:10.1136/bmjopen-2018-025470
Open access
review summarised studies eliciting preferences about 
screening test attributes and healthcare delivery attri-
butes regarding various cancer screening (prostate, 
colon, breast).42 Efficacy, process and cost were signifi-
cant determinants of choice, whereas healthcare delivery 
attributes had mixed effects. The magnitude of effects 
deemed important, however, was not reported.
unanswered questions and future research
The RapidRecs guideline panel identified several 
subgroups of men who might express different distribu-
tion values and preferences regarding prostate cancer 
screening. These included men with family history, 
men of African descent, men with a lower socioeco-
nomic status and men that previously had screening or 
biopsies.1 2 However, none of the studies that met our 
eligibility criteria investigated whether the men’s values 
and preferences differed across subgroups. Identifying 
whether there are differences among men in these 
subgroups regarding their judgements of benefits and 
harms would be important to assess the need for specific 
recommendations.
There is considerable variability in the design and 
reporting of values and preferences studies, which are 
often not amenable for producing absolute estimates of 
effect regarding benefits and harms that would be helpful 
for decision making. More standardised reporting would 
ensure that decision makers are able to use data from 
values and preferences research. Additionally, in this 
systematic review we focused on the values and pref-
erences that can be used to inform the magnitude of 
effect in terms of patient-important outcomes that men 
would consider important to undergo screening. Poten-
tially other values and preferences outcomes, including 
those derived from utilities and qualitative studies, could 
provide additional insights.
Many factors probably play a role in what shapes indi-
vidual decisions, and some of these factors could relate to 
incentives from others: family members, coworkers, media 
as well as recommendations from healthcare providers. A 
challenge of the research in this field is to disentangle 
men’s true values and preferences from responses to such 
incentives. Potential avenues of research may include 
the mapping of screening rates, and their evolution in 
parallel to recommendation of screening campaigns 
across countries. Such research may, however, be limited 
in its conclusion because of the paucity of reliable data, 
and the multiple outside factors that may be at play.
strengths and weaknesses
Our systematic review has several strengths. First, we 
followed the MOOSE guidelines and prospectively 
registered our protocol. Second, we followed rigorous 
systematic review methodology, including a systematic 
comprehensive search using a validated filter for the 
identification of patient’s values and preferences, and 
assessment of study quality.
There are also limitations to our systematic review. 
First, the results reported are intrinsically limited by the 
specific design of the included studies, and the informa-
tion that men were exposed to. For example, most studies 
included several characteristics of the screening options 
(eg, cost, intervals of screening), which may have influ-
enced some men’s willingness to screen more than the 
potential benefits and harms. Second, none of the studies 
explicitly asked participants what thresholds of benefit 
and harm would be important to them. Due to subop-
timal reporting or heterogeneous study design across the 
included studies, we were not able to meta-analyse any 
data, and were limited to narratively summarising the 
included studies. Third, willingness or intention to screen 
may not reflect individuals’ future behaviour,34 thus our 
inferences about acceptability are uncertain.
COnCLusIOns 
The variability of men’s values and preferences, particular 
to the degree that their information needs are met, reflect 
that the decision to screen is highly preference sensitive. 
As a consequence, men considering screening should be 
assisted through shared decision making to ensure that 
they are reaching a decision in line with their values.
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